Boehringer Ingelheim International Gmbh

Sprout Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Marcus Schindler

Dirk Stenkamp

Klaus Rudolf

Stephan Georg Mueller

Philipp Lustenberger

Leo Thomas

Gerald Juergen Roth

Thorsten Lehmann-Lintz

Angelo Ceci

Kirsten Arndt

Eckhart Bauer

Alexander Dreyer

Ralf Lotz

Henri Doods

Kai Gerlach

Rudolf Hurnaus

Ralf R H Lotz

Armin Heckel

Joerg Kley

Marco Santagostino

Stefan Scheuerer

Bernd Nosse

Heather Tye

Alexander Heifetz

Juergen Prestle

Natacha Prevost

Christopher John Brown

Stephan-Georg Mueller

Christoper John Brown

The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.

Use of Flibanserin in the treatment of obesity

Use of flibanserin in the treatment of obesity

The present invention relates to compounds defined by formula I wherein the groups X, Y, W and Rto Rare defined as in claim, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders.

6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them

The invention relates to a method for the treatment of obesity and related diseases comprising the administration of a therapeutically effective amount of Flibanserin.

The present invention relates to compounds of general formula I wherein the groups and radicals B, k, L, U, V, W, X, Y, Z, R, R, have the meanings given in claim. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

Pyridone derivates with MCH antagonistic activity and medicaments comprising these compounds

CGRP antagonists of the formula of which the following are exemplary:

CGRP antagonists

Compounds of formula I wherein the groups and residues A, B, b, X, Y, Z, R, R, R, Rand Rhave the meanings given in claim. The invention further relates to pharmaceutical compositions containing at least one amide according to the invention. As a result of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia, and diabetes.

&#x3b2;-ketoamide compounds with MCH antagonistic activity

The present invention relates to CGRP antagonists of general formula wherein A, U, V, W, X and Rto Rare defined as in claimthe tautomers, diastereomers, enantiomers, hydrates, mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them.

Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions

Alkyne compounds having MCH-receptor antagonistic activity, which are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Compounds of formula (I) wherein A, B, b, W, X, Y, Z, R, R, and Rhave the meanings given in claim, pharmaceutical compositions these compounds, and methods of preventing or treating metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia, and diabetes using these compounds.

Amide compounds with MCH antagonistic activity and medicaments comprising these compounds

The present invention relates to substituted piperidines of general formula wherein R, Rto R, A, X, Z and n are defined as in claim 1, the tautomers, diastereomers, enantiomers, mixtures and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly CGRP-antagonistic properties, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.

Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof

Alkyne compounds of formula I wherein A, B, W, X, Y, Z, R, and Rhave the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

The present invention relates to substituted piperidines of general formulawherein R, Rto R, A, X, Z and n are defined as in claim 1, the tautomers, diastereomers, enantiomers, mixtures and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly CGRP-antagonistic properties, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.

Growing community of inventors

Biberach, Germany

Marcus Schindler